Motixafortide

Motixafortide API

Motixafortide is a synthetic CXCR4 antagonist peptide developed to mobilize hematopoietic stem cells (HSCs) for autologous transplantation and is also being studied in oncology and immunotherapy.

Mechanism & Research:

Motixafortide blocks the CXCR4–SDF-1 axis, leading to:
Rapid stem cell mobilization into peripheral blood
Enhanced immune cell trafficking and tumor infiltration
Potential synergy with checkpoint inhibitors and chemotherapy

It has demonstrated superior stem cell yield compared to existing mobilizers in clinical trials.
API Features (Gentolex Group):

High-purity synthetic peptide
GMP-like production standards
Suitable for injectable formulations

Motixafortide API supports advanced research in stem cell therapy and cancer immunotherapy.